Brian Hansen
Senseonics HoldingsAbout Brian Hansen
Brian Hansen, age 57, joined the Senseonics Board in March 2024; he serves as President of CGM at Ascensia Diabetes Care (Senseonics’ exclusive distribution partner) since February 2024, and holds an MBA from San Diego State University and a BSBA from the University of Missouri . He was appointed pursuant to PHC Holdings Corporation’s investor rights to designate up to two directors, reflecting strategic partner influence on board composition . The Board classifies him as not independent due to his Ascensia role . His tenure at Senseonics began in March 2024 .
Past Roles
| Organization | Role | Tenure | Committees / Impact |
|---|---|---|---|
| Ascensia Diabetes Care | President, CGM | Since Feb 2024 | Leads global CGM commercial strategy; direct linkage to Senseonics’ distribution . |
| Tandem Diabetes Care | EVP & Chief Commercial Officer | Since 2016 | Senior commercial leadership in diabetes devices; relevant market expertise. |
| Adaptive Biotechnologies; Novartis; Gen-Probe; Fisher Scientific | Commercial/leadership roles | Not disclosed | Broad life sciences/diagnostics experience; strengthens commercial perspective. |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Ascensia Diabetes Care | President, CGM | Since Feb 2024 | Senseonics’ exclusive distribution partner; creates related-party proximity . |
| Other public company boards | — | — | No other public company directorships disclosed in Senseonics proxies . |
Board Governance
- Independence: Not independent due to Ascensia role (Senseonics’ exclusive distribution partner for Eversense CGM) .
- Committee assignments: Not listed as a member of Audit, Compensation, or Nominating & Corporate Governance committees for 2024; committee chairs were Prince (Audit), Roeder (Compensation), and DeFalco (Nominating) .
- Meetings and attendance: Board met 4 times in 2024; each director attended ≥75% of Board and relevant committee meetings; all directors attended the 2024 annual meeting .
- Class and term: Listed among Class III directors whose terms expired in 2025 (up for election in 2025) .
Fixed Compensation
| Component | Policy Amount | Hansen 2024 Actual |
|---|---|---|
| Board cash retainer | $40,000 | $0 (elected not to accept director compensation) |
| Audit Committee member / chair | $10,000 / +$10,000 | $0 (not a committee member) |
| Compensation Committee member / chair | $6,500 / +$7,500 | $0 (not a committee member) |
| Nominating & Corporate Governance member / chair | $5,000 / +$5,000 | $0 (not a committee member) |
| Annual equity grant (continuing directors) | $112,500 grant-date fair value (RSU or option) | Not granted in 2024 (exception noted for Hansen) |
| Initial equity grant (new directors) | $225,000 grant-date fair value (RSU or option) | Not disclosed; Hansen declined compensation for Board service |
Hansen elected not to accept compensation for his Board service in light of his Ascensia relationship, mitigating direct-pay conflicts .
Performance Compensation
| Award Type | Grant/Transaction Date | Shares/Units | Price | Vesting / Terms |
|---|---|---|---|---|
| Stock Option (right to buy) | 2025-05-23 (Form 4 filed 2025-05-29) | 1,187,987 | $0.51 | Vesting terms not disclosed in Form 4; reported as “A–Award” |
| Common Stock (award) | 2025-05-23 (Form 4 filed 2025-05-29) | 842,084 | $0.00 | Terms not disclosed; “A–Award” common stock |
- 2024 annual director RSUs of 236,344 units were granted to non-employee directors except Hansen and Sato (Hansen declined compensation) .
- Performance metrics tied to director awards (e.g., TSR, revenue, ESG) are not disclosed in the proxy for non-employee directors .
Other Directorships & Interlocks
| Entity | Nature of Relationship | Interlock / Conflict Signal |
|---|---|---|
| Ascensia Diabetes Care | Exclusive distribution partner for Eversense; Hansen is President of CGM (and SENS director) | Related-party proximity; Board deems Hansen not independent . |
| PHC Holdings Corporation | Investor rights allow designation of up to two directors; PHC designated Hansen and Sato | Strategic shareholder influence on board composition; potential priority of partner interests. |
Expertise & Qualifications
- 30+ years commercial leadership in medical devices, life sciences, and diagnostics; senior roles at Tandem Diabetes Care, Adaptive Biotechnologies, Novartis, Gen-Probe, Fisher Scientific .
- Advanced business education (MBA; BSBA) and diabetes device industry experience; Board cites his substantial diabetes device background as qualification to serve .
- Public remarks in Senseonics’ 2025 results release indicate active engagement on commercial metrics for Eversense 365 launch (as Ascensia CGM President and SENS director) .
Equity Ownership
| Date Reference | Instrument | Amount | % of Shares Outstanding |
|---|---|---|---|
| April 1, 2024 | Common stock | 0 | * (less than 1%) |
| August 1, 2025 | Options exercisable within 60 days | 1,190,269 | * (less than 1%) |
Footnote (13): Brian Hansen beneficially owned 1,190,269 shares via options exercisable within 60 days of August 1, 2025 .
Insider Trades and Awards (Form 4)
| Filing Date | Transaction Date | Type | Security | Quantity | Price | Post-Transaction Ownership | Source |
|---|---|---|---|---|---|---|---|
| 2025-05-29 | 2025-05-23 | A – Award | Stock Option (right to buy) | 1,187,987 | $0.51 | 1,187,987 | |
| 2025-05-29 | 2025-05-23 | A – Award | Common Stock | 842,084 | $0.00 | 842,084 | |
| 2024-04-01 | 2024-03-20 | Form 3 | Stock Option (Right to Buy) | 2,619,048 | $0.502 | 0 (Form 3 initial) |
Governance Assessment
- Independence and conflicts: Hansen is explicitly classified as not independent due to his executive role at Ascensia, Senseonics’ exclusive distribution partner; he was also appointed via PHC investor designation rights, increasing related-party influence—this is a governance risk for board independence and potential conflicts of interest .
- Compensation alignment signal: He declined director compensation for 2024, which mitigates direct-pay conflicts given his partner affiliation; however, substantial equity awards were recorded in May 2025 (options and common stock), increasing alignment but requiring scrutiny of grant rationale and terms in light of his non-independent status .
- Board effectiveness: Not serving on any standing committees (Audit, Compensation, Nominating) limits his formal oversight role; committee chairs and membership otherwise meet independence requirements, which somewhat offsets non-independent director presence .
- Engagement: Attendance meets ≥75% threshold and participation in the 2024 annual meeting indicates baseline engagement, though the absence from committees reduces channel-specific oversight influence .
- Red flags: Related-party proximity (Ascensia distribution), PHC designation right, and non-independence are notable; ongoing monitoring of related-party transactions and equity award practices is warranted. No disclosed pledging or loans; no legal proceedings noted in the cited sections .
Commentary: Hansen’s deep commercial expertise in diabetes devices is additive to product-market execution. Governance risk centers on independence and distribution partner influence; his 2024 compensation waiver is positive, but 2025 equity awards merit careful evaluation for pay-for-influence concerns .